Customer Information about Commercial Dispute with Allergan
THIS IS A COMMERICIAL DISPUTE. IT IS NOT A PRODUCT QUALITY OR SAFETY ISSUE.
Regarding Xeomin®:
Due to a commercial dispute with Allergan, we are restricted from selling or providing Xeomin® in the facial aesthetics market at this time. This is a commercial dispute. It is NOT a product quality or safety issue. We are working to resolve this legal matter as quickly as possible.
WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of XEOMIN (incobotulinumtoxinA) for injection, for intramuscular use, and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.
Please see Full Prescribing Information, including Medication Guide for more information.
Click here to view Press Release
For all inquiries, please email inquiries@merzaesthetics.com
